ES3014398T3 - Compositions for treating pathological calcification and ossification - Google Patents

Compositions for treating pathological calcification and ossification Download PDF

Info

Publication number
ES3014398T3
ES3014398T3 ES14751154T ES14751154T ES3014398T3 ES 3014398 T3 ES3014398 T3 ES 3014398T3 ES 14751154 T ES14751154 T ES 14751154T ES 14751154 T ES14751154 T ES 14751154T ES 3014398 T3 ES3014398 T3 ES 3014398T3
Authority
ES
Spain
Prior art keywords
npp1
polypeptide
npp4
mutant
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14751154T
Other languages
English (en)
Spanish (es)
Inventor
Demetrios Braddock
Ronald Albright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Application granted granted Critical
Publication of ES3014398T3 publication Critical patent/ES3014398T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ES14751154T 2013-02-13 2014-02-12 Compositions for treating pathological calcification and ossification Active ES3014398T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361764297P 2013-02-13 2013-02-13
US201361904786P 2013-11-15 2013-11-15
PCT/US2014/015945 WO2014126965A2 (en) 2013-02-13 2014-02-12 Compositions and methods for treating pathological calcification and ossification

Publications (1)

Publication Number Publication Date
ES3014398T3 true ES3014398T3 (en) 2025-04-22

Family

ID=51354667

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14751154T Active ES3014398T3 (en) 2013-02-13 2014-02-12 Compositions for treating pathological calcification and ossification

Country Status (6)

Country Link
US (7) US9744219B2 (cg-RX-API-DMAC7.html)
EP (2) EP2956163B1 (cg-RX-API-DMAC7.html)
JP (4) JP6894664B2 (cg-RX-API-DMAC7.html)
ES (1) ES3014398T3 (cg-RX-API-DMAC7.html)
PL (1) PL2956163T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014126965A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2956163B1 (en) * 2013-02-13 2024-11-27 Yale University Compositions for treating pathological calcification and ossification
BR112017012928A2 (pt) 2014-12-19 2018-05-15 Alexion Pharma Inc uso de um ectonucleotídeo pirofosfatase fosfodiesterase (npp1); uso de uma composição farmacêutica; e uso de um snpp1 humano recombinante isolado, fragmento ou proteína de fusão deste
CA3176123A1 (en) * 2015-05-19 2016-11-24 Yale University Compositions for treating pathological calcification conditions, and methods using same
JP2018537093A (ja) 2015-11-20 2018-12-20 イエール ユニバーシティ 異所性石灰化障害を治療するための組成物およびそれを使用する方法
US11364284B2 (en) 2016-06-16 2022-06-21 Inozyme Pharma, Inc. Methods of treating myointimal proliferation
BR112019002355A2 (pt) * 2016-08-05 2019-07-16 Yale University composições e métodos para prevenção de acidente vascular cerebral em pacientes pediátricos com anemia falciforme
WO2019067502A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. METHODS FOR IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING RECOMBINANT ECTO-NUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE
CA3099266A1 (en) 2018-05-08 2019-11-14 Yale University Compositions and methods for reducing progression of nephrolithiasis
CN112930397B (zh) * 2018-08-31 2025-05-09 耶鲁大学 Enpp1多肽及其使用方法
EP4162036A1 (en) 2020-06-09 2023-04-12 Inozyme Pharma, Inc. Soluble enpp1 or enpp3 proteins and uses thereof
CN116322742A (zh) * 2020-07-02 2023-06-23 依诺兹梅制药公司 用于治疗同种异体移植物血管病、烟雾病、烟雾病综合征和内膜增殖的组合物和方法
WO2022076848A1 (en) * 2020-10-08 2022-04-14 Inozyme Pharma, Inc. Liver specific production of enpp1 or enpp3

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
US6043056A (en) 1998-11-06 2000-03-28 Incyte Pharmaceuticals, Inc. Cell surface glycoproteins
AU2002258592A1 (en) 2001-03-23 2002-11-25 The Burnham Institute Compositions and methods for modulating bone mineral deposition
US7888372B2 (en) 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
US20070015145A1 (en) 2001-08-14 2007-01-18 Clifford Woolf Nucleic acid and amino acid sequences involved in pain
WO2003072593A2 (en) 2002-02-21 2003-09-04 University Of Virginia Patent Foundation Bone targeting peptides
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
US8846603B2 (en) 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins
AU2011362576B2 (en) 2011-03-11 2017-06-08 Alexion Pharmaceuticals, Inc. NPP1 fusion proteins
EP2956163B1 (en) 2013-02-13 2024-11-27 Yale University Compositions for treating pathological calcification and ossification
BR112017012928A2 (pt) * 2014-12-19 2018-05-15 Alexion Pharma Inc uso de um ectonucleotídeo pirofosfatase fosfodiesterase (npp1); uso de uma composição farmacêutica; e uso de um snpp1 humano recombinante isolado, fragmento ou proteína de fusão deste
CA3176123A1 (en) 2015-05-19 2016-11-24 Yale University Compositions for treating pathological calcification conditions, and methods using same

Also Published As

Publication number Publication date
EP2956163A4 (en) 2017-03-22
JP2016509023A (ja) 2016-03-24
JP2024026704A (ja) 2024-02-28
EP2956163B1 (en) 2024-11-27
US9913881B2 (en) 2018-03-13
US20150359858A1 (en) 2015-12-17
WO2014126965A3 (en) 2014-10-09
EP4523757A2 (en) 2025-03-19
US20170354719A1 (en) 2017-12-14
EP2956163A2 (en) 2015-12-23
US20170252414A1 (en) 2017-09-07
US20200237882A1 (en) 2020-07-30
JP2019196392A (ja) 2019-11-14
US20220152163A1 (en) 2022-05-19
HK1214952A1 (en) 2016-08-12
US10052367B2 (en) 2018-08-21
US20180318401A1 (en) 2018-11-08
US10624958B2 (en) 2020-04-21
JP2021143202A (ja) 2021-09-24
WO2014126965A2 (en) 2014-08-21
JP7420766B2 (ja) 2024-01-23
US9744219B2 (en) 2017-08-29
EP4523757A3 (en) 2025-07-16
US11266722B2 (en) 2022-03-08
JP6894664B2 (ja) 2021-06-30
PL2956163T3 (pl) 2025-04-14
JP6944977B2 (ja) 2021-10-06
US20170333533A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
ES3014398T3 (en) Compositions for treating pathological calcification and ossification
ES2375490T3 (es) Métodos y composiciones para diagnosticar degeneración macular relacionada con la edad.
ES2983910T3 (es) Composiciones para tratar afecciones patológicas de calcificación y métodos que usan las mismas
US9234191B2 (en) Cytotoxic ribonuclease variants
ES2510551T3 (es) Termoestabilización de proteínas
Aspatwar et al. Carbonic anhydrase related protein VIII and its role in neurodegeneration and cancer
US20180230234A1 (en) Inhibition of the complement system
ES2291010T3 (es) Enzimas fosfodiesterasas.
HK40123811A (en) Compositions and methods for treating pathological calcification and ossification
ES2328448T7 (es) 16836, un miembro de la familia de la fosfolipasa c humana y sus usos.
HK1214952B (en) Compositions for treating pathological calcification and ossification
Jiang et al. Crystal structures of human C4. 4A reveal the unique association of Ly6/uPAR/α-neurotoxin domain
US20050037450A1 (en) Novel targets for lithium therapy
ES2328114T3 (es) Regulacion de la serina/treonina proteina quinasa humana de tipo wee1.
AU2003297492A1 (en) Candida kefyr cytosine deaminase